Sungho Bea/LinkedIn
Aug 2, 2025, 17:34
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X:
“Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Apixaban was asso with a lower risk of recurrent VTE and major bleeding compared to rivaroxaban and warfarin in pts initiating oral anticoagulant therapy.”
Title: Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Authors: Sungho Bea, PharmD, PhD; Geetha S. Iyer, PhD; Dae Hyun Kim, MD, MPH, ScD; Kueiyu Joshua Lin, MD, ScD, MPH; Yichi Zhang, MS; Heidi Zakoul, BS; Helen Tesfaye, PharmD, MSc; Katsiaryna Bykov, PharmD, ScD
Read the full article here.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy